Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with the multinational pharmaceutical company Teva Pharmaceutical Industries to launch Epysqli, a biosimilar of the rare disease treatment Soliris (eculizumab), in the U.S. market.

Epysqli is the first hematology biosimilar developed by Samsung Bioepis. Its original drug, Soliris was developed by Alexion, a U.S. company specializing in rare disease treatments. It is used for rare intractable diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is an ultra-high-priced drug that posted global sales of approximately KRW 5 trillion in 2023.